Study of MT027 in Patients with Brain, Meninges, and Spinal Cord Metastatic Solid Tumors

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 1, 2025

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2026

Conditions

Brain (Nervous System) CancersBrain and Central Nervous System TumorsBrain Tumors

Interventions

DRUG

MT027 cells suspension

MT027: CRISPR/Cas9 edited B7H3-specific allogeneic CAR-T cells

Trial Locations (1)

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors

lead

Suzhou Maximum Bio-tech Co., Ltd.

INDUSTRY